Quick Answer
GeneDx Holdings Corp. reported Total Revenue of $427.54 million for fiscal year 2025.
GeneDx Holdings Corp. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $427.54M +40.0% |
$305.45M +50.8% |
$202.57M -13.7% |
$234.69M +10.6% |
$212.19M +18.3% |
$179.32M -8.6% |
| Revenue (ASC 606) | $427.54M +40.0% |
$305.45M +50.8% |
$202.57M -13.7% |
$234.69M +10.6% |
$212.19M +18.3% |
$179.32M -8.6% |
| Net Income | -$21.02M +59.8% |
-$52.29M +70.3% |
-$175.77M +68.0% |
-$548.98M -123.7% |
-$245.39M -1.7% |
-$241.34M -712.5% |
| Diluted EPS | -$0.73 +62.4% |
-$1.94 +73.2% |
-$7.23 +86.5% |
-$53.63 -2262.6% |
-$2.27 +100.0% |
-$47036.00 +82.2% |
| Total Assets | $523.71M +24.9% |
$419.38M +0.1% |
$418.76M -14.7% |
$490.94M +123.9% |
$219.30M -12.9% |
$251.64M |
| Cash and Equivalents | $105.00M +23.2% |
$85.21M -14.5% |
$99.68M -19.6% |
$123.93M +111.3% |
$58.65M -45.8% |
$108.13M |
| Long-Term Debt | $48.18M -7.2% |
$51.91M -1.5% |
$52.69M +743.0% |
$6.25M -66.2% |
$18.50M -2.5% |
$18.97M |
| Stockholders Equity | $308.18M +25.7% |
$245.25M +7.6% |
$228.02M -10.1% |
$253.71M +148.6% |
-$521.83M -58.1% |
-$330.05M -272.1% |
| R&D Expense | $72.03M +57.5% |
$45.72M -21.5% |
$58.27M -32.4% |
$86.20M -18.0% |
$105.16M +44.7% |
$72.70M +108.2% |
| Operating Income | -$13.08M +43.7% |
-$23.21M +87.1% |
-$180.60M +73.0% |
-$667.65M -49.6% |
-$446.15M -84.4% |
-$241.99M -695.7% |
| Gross Profit | $298.17M +53.4% |
$194.40M +116.0% |
$90.01M +436.5% |
-$26.75M -61.1% |
-$16.60M -512.4% |
$4.03M -95.1% |
| Shares Outstanding | 29.25M +4.4% |
28.02M +7.8% |
25.98M +120.7% |
11.77M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $116.74M | +51.9% | +13.7% |
| Revenue (ASC 606) | September 30, 2025 | $116.74M | +51.9% | +13.7% |
| Net Income | September 30, 2025 | -$7.63M | +8.1% | -170.6% |
| Diluted EPS | September 30, 2025 | -$0.27 | +12.9% | -175.0% |
| Total Assets | September 30, 2025 | $493.90M | +20.8% | +6.5% |
| Cash and Equivalents | September 30, 2025 | $95.97M | +65.8% | +29.5% |
| Long-Term Debt | September 30, 2025 | $51.58M | -0.9% | -0.2% |
| Stockholders Equity | September 30, 2025 | $292.26M | +42.9% | +5.5% |
| R&D Expense | September 30, 2025 | $19.83M | +70.0% | +31.5% |
| Operating Income | September 30, 2025 | -$3.25M | +58.2% | -136.3% |
| Gross Profit | September 30, 2025 | $84.53M | +76.7% | +19.2% |
| Shares Outstanding | September 30, 2025 | 28.89M | +5.3% | +0.6% |
- GeneDx Holdings Corp. reported Total Revenue of $427.54 million for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +40.0% in Total Revenue compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Revenue (ASC 606) of $427.54 million for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +40.0% in Revenue (ASC 606) compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Net Income of -$21.02 million for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +59.8% in Net Income compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Diluted EPS of $0.73 per share (loss) for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +62.4% in Diluted EPS compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Total Assets of $523.71 million for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +24.9% in Total Assets compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Cash and Equivalents of $105.00 million for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +23.2% in Cash and Equivalents compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Long-Term Debt of $48.18 million for fiscal year 2025.
- GeneDx Holdings Corp. showed a decrease of -7.2% in Long-Term Debt compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Stockholders Equity of $308.18 million for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +25.7% in Stockholders Equity compared to the prior fiscal year.
- GeneDx Holdings Corp. reported R&D Expense of $72.03 million for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +57.5% in R&D Expense compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Operating Income of -$13.08 million for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +43.7% in Operating Income compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Gross Profit of $298.17 million for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +53.4% in Gross Profit compared to the prior fiscal year.
- GeneDx Holdings Corp. reported Shares Outstanding of 29.25 million shares for fiscal year 2025.
- GeneDx Holdings Corp. showed an increase of +4.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: